ArticlePloS one2025
The role of SLC2A1 in lung adenocarcinoma: From tumorigenesis to patient survival.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A radiomics-based nomogram for preoperatively predicting the invasiveness of nodular lung adenocarcinoma: a multicenter study.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur study aimed at systematically exploring the effect of the solute carrier family 2 Member (SLC2A) genes family on the prognosis and immune landscape of lung adenocarcinoma (LUAD) patients. Furthermore, we sought to determine the SLC2A1 function in LUAD initiation and progression through in vivo and in vitro experiments.
methodsA comprehensive bioinformatics analysis was conducted utilizing online tools and software, including R packages, Gene Set Cancer Analysis (GSCA), cBio Cancer Genomics Portal (cBioPortal), GeneMANIA, STRING, and Xiantao Academic Online databases, to assess the functional implications of the SLC2A gene family in LUAD. Concurrently, in vivo and in vitro experiments at the cellular and animal levels were conducted to ascertain the effects of SLC2A1 gene knockout on LUAD development.
resultsCompared to normal tissues, the SLC2A gene family exhibited significant upregulation across various tumor types, including LUAD, with a low mutation frequency in LUAD. SLC2A1 and SLC2A7 emerged as prognostic biomarkers for LUAD. The receiver operating characteristic (ROC) curve analysis revealed high diagnostic accuracy of SLC2A1 for LUAD. A significant negative correlation was observed between SLC2A1 expression and DNA methylation levels in LUAD, and the gene was closely linked to cellular processes such as cell nuclear division, DNA replication, and metabolism. Moreover, SLC2A1 expression was strongly linked to immune infiltration and regulation across different tumor types. In vitro and in vivo experiments showcased that SLC2A1 inhibition significantly hampered LUAD A549 cell proliferation, migration, and invasion capabilities, as well as tumor growth in nude mice. Finally, our study demonstrated that reduced SLC2A1 expression influenced the expression of molecules within the P53 signaling pathway.
conclusionsThis study elucidates the functional role of the SLC2A gene family in the pathogenesis of LUAD, underscoring the importance of SLC2A1 in LUAD diagnosis, prognosis, and immune response, and presenting SLC2A1 as a promising biomarker for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.